Shots:
The oncology domain accounts for more than 50% of ongoing clinical trials. The global oncology drug market was valued at $185B in 2022 and is predicted to reach $205B by 2030 with a 13% CAGR
Targeted therapy targets specific genes and proteins to prevent them from growing and spreading. In 2022, the market size…
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.
Top 20 Radiopharma Companies Based on Market Cap
Shots:
Integrating scintigraphy with…
Shots:
Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer
While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
Shots:
Amy Taneja, in a stimulating conversation with PharmaShots, shares the highlights of the Jada system, a vacuum-induced hemorrhage control device
Amy describes how the Jada system differs from traditional methods of controlling PPH while explaining how the system works
JADA, which is now being shipped to Chile, Hong Kong, Puerto Rico, New Zealand, and…
Shots:
Justin Schreiber, Chairman, and CEO of, LifeMD, in an illuminating conversation with PharmaShots, discusses the recent partnership with ASCEND Therapeutics
LifeMD, a virtual primary care company, and ASCEND Therapeutics, a leading women's health pharmaceutical company, came together to bring an integrated direct-to-consumer telehealth model to enhance the way women receive care for their menopause…
Shots:
Dr. Lotus Mallbris shares the positive endpoint results of the VIVID-1 P-III study, evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease
While shedding light on the mechanism of mirkizumab, Lotus highlights that available therapies to treat Crohn’s disease often fail to achieve clinical…
Shots:
Paul Moss Professor of Hematology and Deputy Head of the College of Medicine at the University of Birmingham, shares insights from the RWE INFORM study from AstraZeneca
INFORM used record data from 12 million people in the UK to study the relative risk of severe COVID-19 infection in patients with immune suppression
Even though…
Shots:
Real-world evidence (RWE) aims to mitigate the limitations of randomized controlled trials (RCTs) by keeping a constant vigil on the safety and effectiveness of drugs in real-world settings
Phrases such as Real-world data, Randomized Controlled Trials, and Real-World Evidence hold a degree of paramount importance when it comes to safeguarding the health of individuals…
Shots:
At the EASD, AZ announced positive results from the T2NOW P-III study that evaluated the efficacy and safety of Forxiga as an add-on treatment in children and adolescents with T2D receiving metformin, insulin, or both
Helen Yeh, VP, CVRM Therapy Area Biopharmaceuticals Medical at AstraZeneca, and Naim Shehadeh, Professor of Endocrinology, Rambam Health Care…
Illuminating, informative, and engaging, our recent webinar on Successful Drug Discovery-Collaboration Among Multiple Functions with Eurofins Advinus, was an energy-packed session that highlighted the intricacies of the drug discovery process. The webinar delved deep into the nuances that are necessary for a successful drug discovery. The session was filled with stimulating case studies, highlighting crucial aspects like…

